Exp Clin Endocrinol Diabetes 2011; 119(3): 156-162
DOI: 10.1055/s-0030-1267244

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Efficacy and Acceptability of Lanreotide Autogel® 120 mg at Different Dose Intervals in Patients with Acromegaly Previously Treated with Octreotide LAR

J. Schopohl1 , C. J. Strasburger2 , D. Caird3 , K. Badenhoop4 , F. Beuschlein1 , M. Droste5 , U. Plöckinger6 , S. Petersenn7 for the German Lanreotide Study Group.
  • 1Medizinische Klinik Innenstadt, Ludwig-Maximilians University, Munich, Germany
  • 2Charité Campus Mitte, Berlin, Germany
  • 3Ipsen Pharma GmbH, Ettlingen, Germany
  • 4University Clinic Frankfurt am Main, Germany
  • 5Endocrinological Practice Oldenburg, Germany
  • 6Charité Campus Virchow, Germany
  • 7University Clinic Essen, Germany
Further Information

Publication History

received 07.06.2010 first decision 04.08.2010

accepted 29.09.2010

Publication Date:
17 November 2010 (online)


Objective: To assess the efficacy of different dosing intervals of lanreotide, Somatuline Autogel® (Lan-ATG) 120 mg in patients with acromegaly, previously treated with octreotide, long-acting release (Oct-LAR).

Patients and study design: Patients previously on Oct-LAR 10, 20, or 30 mg were switched to 6 repeated deep subcutaneous injections of Lan-ATG 120 mg at intervals of 56, 42, or 28 days, respectively. After the third injection, dose intervals were adjusted on the basis of insulin-like growth factor 1 (IGF-1) levels.

Results: The ITT (Intention To Treat) population comprised 35 patients who received at least one dose of study medication and at least one post-baseline efficacy assessment. Overall, 62.9% (n=22) of patients had normalised IGF-1 levels with Lan-ATG at study end (one injection interval after the 6th injection of Lan-ATG), which was similar to the proportion at baseline (60.0% [n=21]). QoL did not change from baseline to study end. Patient preference for Lan-ATG was highest in the 56-day dosing interval group: 71%, 54% and 41% of the patients in the 56, 42 and 28 day groups, respectively, expressed a preference for treatment with Lan-ATG (preference for Oct-LAR: 29%, 9% and 35%, respectively, while the remainder had no preference).

Conclusion: Lan-ATG 120 mg injected at intervals of 56, 42 and 28 days provided equivalent hormonal control and QoL to Oct-LAR 10, 20 and 30 mg injected every 28 days, respectively. The proportion of patients preferring Lan-ATG treatment was greater in the longer injection interval groups.


1 >2.0 ng/ml was the value specified in the study protocol but more recently, a cut off value of >0.4 ng/ml has been defined ([Giustina et al. 2010]).


Prof. Dr. med. J. Schopohl

Medizinische Klinik Innenstadt

Klinikum der Universität


Ziemssenstraße 1

80336 München


Phone: +49/089/5160 2333

Fax: +49/089/5160 2272

Email: jochen.schopohl@med.uni-muenchen.de